Lentiviral-Vector on Bioeconhttps://en.bioecon.ru/technologies/lentiviral-vector/Recent content in Lentiviral-Vector on BioeconHugoen-USSat, 11 Jul 2026 13:30:18 +0700CAR-T cell therapyhttps://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.TCR therapy (T-cell receptor engineered T cells)https://en.bioecon.ru/technology/tcr-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/tcr-therapy/Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune’s Tecelra and Immunocore’s Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.